Healthcare Industry News: colonoscopy
News Release - September 11, 2006
E-Z-EM Signs Group Purchase Agreement for Empower Injectors with AmerinetLAKE SUCCESS, N.Y.--(HSMN NewsFeed)--Sept. 11, 2006--E-Z-EM, Inc. (NASDAQ:EZEM ) today announced that Amerinet, one of the nation's largest group purchasing organizations, has awarded the Company a non-exclusive purchasing agreement for its EmpowerŽ line of CT injector systems. This agreement is the first for Empower products E-Z-EM has secured with a major Group Purchase Organization, and will provide Amerinet's more than 2,100 hospital members access to preferred contract pricing for Empower injectors. The three-year agreement is effective as of September 1, 2006.
The award winning Empower product line is the only family of CT injectors on the market powered by the IRiSCT(TM) Injector Reporting Information System, a powerful software application that automatically captures operational data from several important functions of the injector. When used to network all injector systems in a facility, IRiSCT helps consolidate data from the entire Radiology department, facilitating quantitative analysis and simplifying budgeting, while allowing busy administrators to focus on other critical management tasks. Empower injectors are also available with patented EDA(TM) technology that can help detect contrast extravasation.
Commenting on the release, Anthony A. Lombardo, president and chief executive officer of E-Z-EM, said, "This agreement will give Amerinet's participating members an opportunity to obtain preferred pricing for our award winning Empower products while maintaining their contract compliance. Though we currently market Empower injectors to some of these users on a non-contract basis, this purchase agreement will eliminate compliance as a competitive issue while simultaneously increasing our profile within the Amerinet network. We are especially pleased that Amerinet will support the launch of this new agreement with a super promotion period, during which additional discounts will be available. The agreement is the first of its kind for our injector products, and we are very pleased to be working with Amerinet to bring Empower products to their membership."
About E-Z-EM, Inc.
E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company is the developer of VoLumenŽ -- the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and PET/CT studies. The Company also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. The Company is also the exclusive manufacturer and marketer of Reactive Skin Decontamination Lotion (RSDL) for first-responder organizations and military services in many countries. RSDL is a liquid skin decontaminant that breaks down chemical agents such as Sarin or VX in seconds, leaving a non-toxic liquid that can be washed away with water.
The statements made in this document contain certain forward-looking statements. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company's control. Such risks and uncertainties include: the ability of the Company to develop its products; the impact and future sales derived from the Amerinet purchase agreement for Empower products, market acceptance and sales of VoLumenŽ; future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, price increases of raw materials and components, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on Form 10-K for the fiscal year ended June 3, 2006. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.